Myeloid Therapeutics, a company developing in vivo cell therapies for cancer as well as a novel gene editing technology, has ...

Tariffs on pharmaceutical products that President Donald Trump has teased for weeks are one step closer to fruition after the ...

The centerpiece of Bristol Myers Squibb’s $13 billion MyoKardia acquisition failed a Phase 3 study meant to expand the ...

The government is fighting in court for a plan to cut spending on overhead research costs for grantees. Primate centers fear ...

A panel of experts who decide the national immunization schedule will meet on Tuesday for the first time in 2025, providing ...

Ab­b­Vie and San­doz have re­solved their patent dis­pute over Ab­b­Vie’s block­buster im­munol­o­gy drug Rin­voq. San­doz ...

The American Medical Association is urging Optum, a unit of UnitedHealth Group, to ease up on recouping the loans it provided ...

After accumulating $86 billion in global sales, Amgen is still trying to keep Enbrel biosimilars off the market, Sandoz ...

In a development landscape as extensive as obesity, we think Pfizer could be better served by looking outside,' Stifel ...

Commerce Secretary Howard Lutnick has indicated more specific timelines as to when pharma tariffs could surface, noting they ...

Verve Therapeutics is trying to swerve the gene editing industry downturn with new results on a potential one-time treatment to lower cholesterol. The experimental gene editing therapy cut bad ...